Efficacy of Topical Cyclosporine A for Treatment and Prevention of Graft Rejection in Corneal Grafts With Previous Rejection Episodes

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

The use of topical Cyclosporine A early after an episode of endothelial graft rejection after penetrating keratoplasty and continuing its administration for 6 months can reduce the course of that episode and recurrence of the rejection.

• Phase: Phase 4

Details

• Lead Sponsor: Shahid Beheshti University of Medical Sciences
• Treatments: Cyclosporine; Cyclosporins

Criteria

Inclusion Criteria:

• Penetrating keratoplasty in eyes without vascularization

Exclusion Criteria:

• History of previous intraocular surgery